Baxter International Faces Class Action Over Novum IQ Pump Safety Concerns
- Baxter International faces a class action lawsuit for allegedly misleading investors about the safety of its Novum IQ Pump.
- The lawsuit claims Baxter knew about malfunctions in the Novum LVP but failed to act, risking patient safety.
- Baxter's stock dropped over 22% following a pause in Novum LVP shipments, raising concerns about its financial stability.
Baxter International Faces Class Action Lawsuit Over Novum IQ Pump Safety Allegations
Baxter International, Inc. finds itself at the center of a class action lawsuit initiated by Robbins Geller Rudman & Dowd LLP. The lawsuit targets investors who acquired Baxter common stock between February 23, 2022, and July 30, 2025. Allegations include violations of the Securities Exchange Act of 1934, centered on misleading statements made by Baxter and certain executives regarding the safety and reliability of its Novum IQ Large Volume Pump (Novum LVP). The complaint asserts that Baxter failed to disclose systemic defects in the device, which reportedly led to serious malfunctions such as underinfusion and complete non-delivery of fluids—issues that pose significant risks to patient safety.
The lawsuit further claims that Baxter was aware of incidents involving Novum LVP malfunctions and associated injuries but did not take adequate remedial action. This lack of transparency raises serious concerns about the company's commitment to patient safety and device reliability. On July 31, 2025, in response to these escalating issues, Baxter announced a voluntary pause in shipments and installations of the Novum LVP. The uncertainty surrounding the resumption of these operations has intensified scrutiny of the company's practices, contributing to a notable drop in Baxter’s stock price by over 22%.
As the legal proceedings unfold, investors who have suffered losses are encouraged to participate in seeking lead plaintiff status. With a deadline set for December 15, 2025, stakeholders are urged to provide their information to potentially take part in this significant case. The outcome could have substantial implications for Baxter's corporate governance and operational strategies, as well as its reputation within the healthcare sector.
In additional news, Baxter has recently announced a reduction in its financial guidance for 2025, marking a troubling trend for the company amid ongoing operational challenges and market pressures. These adjustments have raised concerns regarding Baxter's ability to stabilize and achieve its growth targets. The situation reflects broader competitive dynamics within the healthcare industry, necessitating close observation of Baxter's strategic responses to these challenges.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

